2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Shambavi Richard, MD, highlights the rapidly evolving armamentarium in multiple myeloma.
Shambavi Richard, MD, assistant professor of medicine, hematology, and medical oncology, Center of Excellence for Multiple Myeloma, Mount Sinai Hospital, highlights the rapidly evolving armamentarium in multiple myeloma.
Historically, treatment options in multiple myeloma elicited suboptimal responses for patients, explains Richard. However, with research focused on deepening and sustaining remissions, the field appears to be entering a new era of improved patient management.
Moreover, in recent years, minimal residual disease (MRD) has become a critical end point in several clinical trials, Richard says. Now, MRD is starting to establish a role in clinical practice.
With the approval of multiple novel therapies, the field continues to evolve with the hope of cure in the not-too-distant future, Richard concludes.